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Abstract
Background: The authors analyzed data from Polish national POL-TAVI registry in terms of 
paravalvular leak (PVL) occurrence after transcatheter aortic valve implantation (TAVI) and 
its impact on clinical outcomes.
Methods: A total of 331 patients with severe aortic stenosis underwent TAVI (Edwards 
Sapien, n = 141; CoreValve, n = 190). The grade of PVL and survival rate were assessed at 
6-month follow-up.
Results: One hundred and eighty-one (54.7%) patients developed mild PVL, and 22 (6.6%) 
— moderate PVL after TAVI. No severe PVLs were observed. Occurrence of moderate PVL 
was device dependent and more frequent in the CoreValve group (p = 0.02). Larger CoreValve 
device used correlated with the grade of PVL (Spearman: r = 0.19; p = 0.01), but for Edwards 
Sapien devices this correlation was inverted (Spearman: r = –0.62; p = 0.01). Six-month 
mortality rate was not significant between patients with no or mild PVL compared to those 
with moderate PVL (p = 0.12).
Conclusions: The PVL occurrence remains a frequent problem after TAVI and is device de-
pendent, more common with Edwards 23 mm valve and 31 mm CoreValve prosthesis. (Cardiol J  
2016; 23, 2: 163–168)
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Introduction
Transcatheter aortic valve implantation (TAVI) 
is a less invasive treatment option for elderly, 
high-risk patients with symptomatic severe aortic 
stenosis (AS) than surgical aortic valve replace-
ment (AVR); it improves survival [1] and quality 
of life [2] compared with medical treatment in 
inoperable patients. However, post-implantation 
paravalvular leak (PVL) remains a significant 
complication associated with TAVI, which may 
cause a higher mortality rates afterwards [3]. 
We sought to investigate the early- and medium-
term outcomes of TAVI in patients with PVL. 
Data from the Polish national POL-TAVI registry 
were analyzed.
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Methods
The POL-TAVI registry is an obligatory Polish 
registry for TAVI procedures in Poland. Accord-
ing to data reported by the registry, there were 
381 TAVI implantations performed in Poland in 
2013. Data of 331 (86.9%) patients, for whom data 
regarding device type and PVL assessment were 
collected in POL-TAVI registry, were assessed. 
Fifty patients withdrew their consent for data 
analysis or data were incomplete for assessment. 
All patients who were meant to undergo TAVI were 
evaluated by a dedicated multidisciplinary Heart 
Team [4, 5]. Clinical decision-making was based 
on a multimodality screening assessment including 
evaluation of surgical risk by logistic EuroScore I 
or Society of Thoracic Surgeons score. Additional 
risk criteria included porcelain aorta, advanced 
liver cirrhosis, severe neurological impairment, 
and frailty due to physician’s judgment. Aortic an-
nulus diameter was assessed with transesophageal 
echocardiography and computed tomography (CT) 
in each case. All procedures were performed by 
a dedicated hybrid team. Only Edwards Sapien, 
Ewards Sapien XT (Edwards Sapien, Irvine, United 
States) and Medtronic CoreValve (Medtronic Core-
Valve, Santa Rosa, United States) devices were 
used in this subset of patients. PVL at hospital 
discharge was graded as absent or mild, moder-
ate and severe, according to the Valve Academic 
Research Consortium-2 (VARC 2) criteria with the 
use of transthoracic echocardiography [6]. We di-
vided patients according to PVL degree into group 
PVL no higher than mild (no + mild), and at least 
moderate (moderate + severe).
Definitions
Cathlab is an examination room in a hospital 
with a single X-ray generator source and an image 
intensifier used to visualize the coronary arteries 
and treatment.
Hybrid operating room is a surgical theater 
that is equipped with advanced medical ima ging 
devices such as fixed C-Arms, CT scanners 
enabling minimally invasive surgery or other 
procedures.
Operating room — operating theater for car-
diosurgeons equipped with a mobile C-arm.
Statistical analysis
All statistical analyses were performed using 
JMP Software (version 9.0.0; SAS Institute, Cary, 
NC, USA). Results were presented as numbers of 
patients (percentages) or median (interquartile 
range [IQR]) where applicable. Correlation be-
tween PVL and other evaluated parameters were 
tested using c2 or Pearson test, when applicable. 
Place of treatment and atrial fibrillation (AF) vari-
ables were introduced into nominal logistic model 
to assess odds ratio (OR) for each parameters 
included into model. All tests were two-tailed, 
and a p value < 0.05 was considered statistically 
significant.
Results
POL-TAVI registry collected the data regard-
ing aortic valve device which was implanted and 
assessment of post-procedural PVL of 331 patients. 
Baseline patient demographic, clinical and echo-
cardiographic variables are presented in Table 1. 
Median of patients’ age was 80 years and 56% 
of patients were female. All patients had severe 
Table 1. Baseline demographic and clinical  
characteristic of enrolled patients.
Variable N = 331
Age [years] 80 (75–84) 
Female 56%
Body mass index [kg/m2] 26.8 (23.9–29.7)
Arterial hypertension 86%
Diabetes mellitus 36%
Previous myocardial infarction 26%
Previous CABG 9.7%
Atrial fibrillation 36%
Previous pacemaker 14%
COPD 16%
Chronic renal failure 63%
Dialysis 2.4%
CCS I–II 41%
CCS III–IV 59%
NYHA I–II 23.5%
NYHA III–IV 76.5%
Logistic EuroScore I [%] 15.7 (9.5–24.8)
STS score [%] 5.3 (3.1–11.5)
Aortic valve parameters:
Pressure gradient max [mm Hg] 80 (65–98)
Pressure gradient mean [mm Hg] 50 (40–63)
Aortic valve area [cm2] 0.7 (0.6–0.8)
Left ventricular ejection fraction [%] 55 (45–60)
Data are presented as median values and interquartile range or 
numbers (percentages); CABG — coronary artery bypass grafting; 
COPD — chronic obstructive pulmonary disease; CCS — Canadian 
Cardiovascular Society scale; NYHA — New York Heart Association 
class; STS — Society of Thoracic Surgeons
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symptomatic AS — median aortic valve area was 
0.7 cm2 (IQR 0.6–0.8). One hundred and forty-
-nine (45%) TAVI procedures were performed in 
the cathlab. Thirty-two (9.7%) procedures were 
performed in the operating room. One hundred 
and fifty (45.5%) procedures were carried out in 
the hybrid operating room. Edwards Sapien and 
Edwards Sapien XT prostheses were implanted 
in 141 patients (16 and 125, respectively, 42.6%) 
and Medtronic CoreValves were implanted in 190 
patients (57.4%). A detailed distribution of device 
size is presented on Figure 1A, B. Echocardiog-
raphy assessment after TAVI procedure revealed 
that 181 (54.7%) patients developed mild PVL and 
22 (6.6%) patients — moderate PVL. No severe PVLs 
were observed at those time points. PVL grade 
remained stable in echocardiography assessment 
after 6 months of follow-up. Patients with missing 
echocardiographic assessment of the PVL were 
excluded from this analysis. Occurrence of moder-
ate PVL was device dependent and more frequent 
in CoreValve group (p = 0.02). Moreover, PVL 
after TAVI was observed more often with Edwards 
23 mm valve and 31 mm CoreValve prostheses. 
For the CoreValve devices, bigger size of the implant-
ed device is correlated with larger PVL (Spearman: 
r = 0.19; p = 0.01, Fig. 2), but for Edwards Sapien 
devices this correlation is inverted (Spearman: 
r = –0.62; p = 0.01, Fig. 3A, B). No significant cor-
relation between PVL and device size was found in 
the Edwards Sapien XT group (Spearman: r = –0.06; 
p = 0.52) and with whole Edwards (Sapien and 
Sapien XT) group (Spearman: r = –0.15; p = 0.08). 
Patients with AF had 5 times higher risk of mod-
erate PVL (p < 0.01) than patients without AF. 
Patients treated in hybrid room had 3 times higher 
risk of moderate PVL than patients treated in the 
cathlab (p = 0.03). Patients treated in the operation 
room had 6 times higher risk of moderate PVL than 
patients treated in the cathlab (p = 0.04) (Fig. 4). 
Median of the procedure time was 135 min (IQR: 
105; 180). Median of the fluoroscopy time was 
24 min (IQR: 17; 32.875). Median of the contrast 
medium used was 180 mL (IQR: 140; 210). The 
highest fluoroscopy time was observed in a group 
of patients with moderate PVL (Fig. 5). We also 
Figure 1. A, B. Aortic valve device size distribution.
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Figure 2. Paravalvular leak (PVL) in a group of CoreValve devices depended on device size.
Figure 3. A. Paravalvular leak (PVL) in a group of Edwards Sapien devices depended on device size; B. Paravalvular 
leak (PVL) in a group of Edwards Sapien and Sapien XT devices depended on device size.
assessed a 6-month mortality rate that was not 
significant between patients with no or mild PVL 
compared to those with moderate PVL (p = 0.12, 
Fig. 6).
Discussion
TAVI is characterized by a high prevalence of 
postprocedural PVL, being moderate-to-severe in 
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5–40% of patients [7–12]. Moderate-to-severe PVL 
had been previously identified as an independent 
predictor of late mortality (30 days up to 1 year) 
after Medtronic CoreValve implantation [9]. An 
impact of PVL on medium-term prognosis has 
been recently demonstrated also for the Edwards 
SAPIEN prosthesis [12, 13]. Our aim was to assess 
the incidence of moderate-to-severe PVL after 
TAVI. Our study examined a cohort of patients 
from the Polish national POL-TAVI registry, in-
cluding only patients successfully implanted and 
discharged alive. According to the registry data, 
181 (54.7%) patients developed mild PVL, 22 
(6.6%) — moderate PVL after 6 months and no 
severe PVLs were observed. Meta-analyses of 
multiple studies in the high-risk population show 
that for either valve type, moderate or severe PVL 
is an important determinant of mortality [14, 15]. 
However, in our study, the mortality rate after 
6 months was not significant, probably due to low 
patient count and relatively short period of follow-
up (6 months). Thus, the accurate assessment of 
this complication is an important means for deter-
mining the effectiveness of procedure and should 
be followed-up in a subset of patients undergoing 
TAVI. Occurrence of moderate PVL was device 
dependent and more frequent in the CoreValve 
group. Moreover, for the CoreValve devices bigger 
size of implanted device is correlated with larger 
PVL. This data is accordant with results of other 
PVL studies [16]. We found an inverted correlation 
between the degree of PVL and Edwards Sapien 
device. This could occur due to the possible siz-
ing problem of the device with respect to aortic 
annulus diameter and learning curve. Operators 
could eventually downsize the potentially used 
Figure 5. Fluoroscopy time in a group with different paravalvular leak (PVL).
Figure 4. Risk of moderate paravalvular leak occurrence 
in case of atrial fibrillation and different treatment place 
(nominal logistic fit). Figure 6. Six-month mortality; PVL — paravalvular leak.
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prosthesis and their decision was affected by the 
annulus rupture possibility if they chose too big 
valve. Moreover, we found that at least moderate 
PVL after TAVI is predicted by preexisting AF and 
implantation site. There has been no data available 
so far to support our finding. Differences in PVL oc-
currence depending on procedure site are probably 
due to learning curve of the staff and worse quality 
of imaging in the operating room. Babaliaros et al. 
[16] compared TAVI via transfemoral approach in 
the cathlab and the hybrid operating room. Moder-
ate or severe paravalvular leak and device success 
were similar in the cathlab and hybrid room groups 
(3% vs. 5.8%, p = 0.4; 90% vs. 88%, p = 0.79, 
respectively) at 30 days.
Limitations of study
The study involved a relatively small sample 
size (n = 331) and the data was analyzed retro-
spectively as registry data. Data was submitted 
by 20 centers performing TAVI procedures with 
different grade of completeness. Data submission 
was not monitored. Correlation of AF and PVL 
might be a finding by chance due to the number 
of patients. Most likely root angiography is the 
preferred method, since echocardiography has its 
clear limitation in PVL assessment. The precise 
quantification of the magnitude of PVL still remains 
a challenging problem.
Conclusions
TAVI is an efficient treatment for patients with 
severe AS but may cause a PVL. The occurrence 
of PVL is associated with device type, size and de-
fined comorbidities. PVL after TAVI was observed 
more often with Edwards 23 mm valve and 31 mm 
CoreValve prosthesis.
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